Kentaro Okunushi

JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.

Yasuhiro Watanabe, N. Anzai, N. Shimojo, 2020, Journal of pharmacological sciences.

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase

Yasuhisa Fujii, A. Hata, T. Ariga, 2019, The Lancet.

Case Report : Focal myocarditis with complete atrioventricular block as an initial presentation of rheumatic fever

H. Takaoka, Yoshio Kobayashi, N. Shimojo, 2017 .

Sivelestat sodium hydrate treatment for refractory Kawasaki disease

Y. Kohno, H. Hanaoka, N. Shimojo, 2019, Pediatrics international : official journal of the Japan Pediatric Society.

Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203

H. Matsubara, N. Anzai, Masaya Uesato, 2019, AntiCancer Research.

Facial nerve palsy associated with atomoxetine-induced hypertension

K. Fujii, N. Shimojo, T. Shiohama, 2019, Brain and Development.

Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma

S. Sakamoto, N. Anzai, Y. Ikehara, 2019, Scientific Reports.

Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation.

N. Anzai, Kyoko Takahashi, T. Mashino, 2018, Bioorganic & medicinal chemistry letters.

Case report: Progressive pulmonary artery hypertension in a case of megalencephaly-capillary malformation syndrome

Mitsuhiro Kato, H. Saitsu, M. Nakashima, 2023, Frontiers in genetics.